Hyperfine, Inc. HYPR
- Market cap
- $84.4M
- P/E
- 0.0×
Follow HYPR
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | 6.85 | 0.68 | 0.77 | 0.76 | 0.53 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | 16.61 | 7.50 | 3.28 | 1.39 | 2.22 |
High Price
|
|||
| — | — | — | — | 2 | 193 | 136 | 131 | 111 | 102 |
Employees
|
|||
| — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | 0 | 1 | 7 | 11 | 13 | 14 |
Revenue
|
|||
| — | — | — | — | (162.24%) | (78.01%) | 13.31% | 43.12% | 45.70% | 49.79% |
Gross Margin
|
|||
| — | — | — | — | (23) | (65) | (73) | (44) | (41) | (36) |
EBT
|
|||
| — | — | — | — | (7,968.37%) | (4,334.96%) | (1,073.73%) | (401.00%) | (315.90%) | (262.29%) |
EBT Margin
|
|||
| — | 0 | — | — | (23) | (65) | (73) | (44) | (41) | (36) |
Net Income
|
|||
| — | — | — | — | 0 | 1 | 1 | 1 | 1 | 1 |
Depreciation
|
|||
| — | — | — | — | 0.19 | 0.41 | 0.10 | 0.15 | 0.18 | 0.17 |
Revenue/Sh
|
|||
| — | — | — | — | (15.38) | (17.57) | (1.04) | (0.62) | (0.56) | (0.43) |
Earnings/Sh
|
|||
| — | — | — | — | (14.13) | (12.78) | (1.03) | (0.59) | (0.54) | (0.34) |
Cash Flow/Sh
|
|||
| — | — | — | — | (1.03) | (0.73) | (0.01) | (0.01) | (0.01) | (0.01) |
Capex/Sh
|
|||
| — | — | — | — | (15.16) | (13.52) | (1.04) | (0.60) | (0.54) | (0.36) |
Free CF/Sh
|
|||
| — | — | — | — | (40.09) | 50.45 | 1.76 | 1.18 | 0.68 | 0.50 |
Book Value/Sh
|
|||
| — | — | — | — | 2 | 4 | 70 | 71 | 72 | 82 |
Shares
|
|||
| — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | 0.00 | 17.89 | 8.58 | 7.30 | 4.94 | 5.91 |
PS Ratio
|
|||
| — | — | — | — | 12,839.40 | 0.14 | 0.47 | 0.95 | 1.30 | 1.95 |
PB Ratio
|
|||
| — | — | — | — | 0.00 | (109.89) | (8.77) | 0.43 | 2.02 | 3.25 |
EV/Sales
|
|||
| — | — | — | — | 0.00 | 3.30 | 0.82 | (0.11) | (0.67) | (1.51) |
EV/FCF
|
|||
| — | — | — | — | (22) | (47) | (72) | (42) | (39) | (28) |
Op' Cash Flow
|
|||
| — | — | — | — | (2) | (3) | (1) | (1) | 0 | (1) |
Capex
|
|||
| — | — | — | — | (23) | (50) | (73) | (43) | (39) | (29) |
FCF
|
|||
| — | — | — | — | 64 | 182 | 120 | 80 | 45 | 39 |
Working Cap'
|
|||
| — | — | — | — | 0 | — | — | — | — | — |
Total Debt
|
|||
| — | — | — | — | (64) | (191) | (118) | (76) | (38) | (36) |
Net Debt
|
|||
| — | — | — | — | (61) | 186 | 124 | 84 | 49 | 41 |
Sh' Equity
|
|||
| — | — | — | — | (65.51%) | (47.34%) | (43.48%) | (38.76%) | (53.19%) | (62.32%) |
ROA
|
|||
| — | — | — | — | 0.00% | 0.00% | (842.69%) | (349.88%) | (237.66%) | (467.02%) |
ROIC
|
|||
| — | — | — | — | (37.43%) | (103.62%) | (47.21%) | (42.51%) | (61.03%) | (79.01%) |
ROE
|
|||
Hyperfine, Inc. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SERA Sera Prognostics, Inc. | $83.2M | 0.0× | Compare |
| LNSR LENSAR, Inc. | $86.9M | 2.4× | Compare |
| LUNG Pulmonx Corporation | $81.6M | 0.0× | Compare |
| ZOMDF Zomedica Corp. | $95.4M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ECOR electroCore, Inc. | $102.3M | 0.0× | Compare |
| CVRX CVRx, Inc. | $67.4M | 0.0× | Compare |
| MYO Myomo, Inc. | $64.6M | 0.0× | Compare |
| APYX Apyx Medical Corporation | $119.2M | 0.0× | Compare |
Hyperfine, Inc. (HYPR) key facts
- Hyperfine, Inc. (HYPR) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- Hyperfine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 million, up 5.22% from fiscal 2024.
- Hyperfine, Inc. reported a net loss of $35.6 million, or a loss of $0.43 per share, for fiscal 2025.
- As of September 25, 2026, HYPR traded at $0.81, a market capitalization of $84.4 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 4.9× sales.
- Return on equity was −79.0% and debt-to-equity 0.36.
Hyperfine, Inc. (HYPR) Latest News
15 Sep
Hyperfine completed enrollment in the Contrast PMR Study to support submission for expanding Swoop System indications with contrast agents. Study enrollment completion advances regulatory submission for broader Swoop System use.
26 Aug
Hyperfine reports over 3,000 scans completed and NEURO PMR publication during first year of neurology office launch. Scan volume and publication reflect gradual adoption gains for portable MRI systems without major strategic shifts.
20 Aug
Hyperfine receives FDA clearance for its next Optive AI software, which improves image quality, clinical utility, and ease of use for the Swoop portable MRI system across care settings. FDA clearance for upgraded AI software directly strengthens Hyperfine's core product capabilities and competitive position in portable MRI.
13 Aug
Hyperfine reported Q2 2026 financial results during its earnings call, covering revenue, net loss, cash position, and updates on portable MRI system sales, regulatory progress, and commercial strategy. Quarterly earnings provide updated financial metrics and operational guidance that can shift near-term investor sentiment but rarely alter long-term company trajectory.
7 Aug
Hyperfine Inc (HYPR) posted Q2 2026 revenue growth of 45% driven by strong system sales. 45% revenue increase signals major sales momentum that can shift financial trajectory and investor views.
Hyperfine, Inc. reported Q2 2026 financial results and business updates during its earnings call, covering revenue, operational progress, and forward outlook. Quarterly earnings provide performance details that may influence short-term sentiment without fundamentally altering company trajectory.
6 Aug
Hyperfine reported Q2 earnings call highlights covering financial results, operational updates and forward outlook for its portable MRI systems. Q2 earnings provide updated financial metrics and guidance that can moderately shift near-term investor views on Hyperfine's trajectory.
Hyperfine, Inc. posted a Q2 net loss and missed revenue estimates. Q2 loss and revenue miss indicate weaker financial results likely to pressure near-term stock performance.
Hyperfine, Inc. reported its second quarter 2026 financial results. Quarterly financial results provide data that can shift near-term investor sentiment and valuation.
30 Jul
Hyperfine releases multiple peer-reviewed publications expanding clinical evidence for the Swoop system across more sites of care. Publications add clinical validation that may support broader Swoop adoption without immediate major financial or strategic shifts.
2 Jul
Hyperfine launches next-generation Swoop MRI system in Europe. Next-generation Swoop MRI launch expands Hyperfine product reach into Europe.
Hyperfine, Inc. launches its next-generation Swoop MRI system in Europe. European launch of next-generation Swoop MRI system expands Hyperfine market reach and revenue potential.
1 Jul
Hyperfine launches next-generation Swoop portable MRI system in Europe. European launch of next-generation Swoop expands Hyperfine revenue opportunities and market reach.
22 Jun
Hyperfine forms Global Neurosurgery Advisory Council to drive portable MRI adoption in neurosurgical care. Advisory council aids portable MRI expansion strategy without immediate revenue or market-altering effects.
18 Jun
Hyperfine Swoop system scan volumes hit record levels across multiple US care sites. Record US scan volumes signal rising product adoption with moderate upside for revenue and sentiment.
26 May
Hyperfine, Inc. (HYPR) will join the Russell 2000® and Russell 3000® Indexes. Index inclusion typically increases visibility and liquidity for small-cap firms without altering core operations.
22 May
Hyperfine presents PRIME Study results showing portable MRI substantially reduces time to imaging in emergency departments. Positive PRIME study results on portable MRI time savings in emergency settings support faster commercial adoption and revenue growth.
13 May
Hyperfine Inc. (HYPR) Q1 2026 earnings call highlighted surging revenue and strategic advances. Revenue surge and strategic advances indicate significant positive momentum for HYPR's financial performance and market trajectory.
Hyperfine, Inc. held Q1 2026 earnings call covering financial results, operational updates, and outlook. Quarterly earnings call delivers financial metrics and guidance that moderately shape near-term investor sentiment.
12 May
Hyperfine, Inc. (HYPR) reported first quarter 2026 financial results. Quarterly earnings reports like Q1 2026 results typically drive significant shifts in stock price, investor sentiment, and future trajectory.
Hyperfine, Inc. (HYPR) released Q1 earnings call highlights detailing financial results, operational progress, and future outlook. Q1 earnings highlights reveal financial performance and strategic updates with moderately noticeable influence on HYPR's market trajectory.
Hyperfine, Inc. (HYPR) reported a Q1 loss but beat revenue estimates. Revenue beat despite Q1 loss moderately boosts short-term market sentiment while highlighting ongoing profitability challenges.
7 May
BTIG initiates coverage of Hyperfine, Inc. (HYPR) with a bullish outlook. BTIG's bullish coverage initiation boosts investor sentiment and signals potential stock upside for HYPR.
29 Apr
Hyperfine's Swoop® system launched as India's first portable MRI for bedside brain imaging at the country's leading medical institution. Introduction of Swoop® as India's first portable MRI at a top institution marks significant international market expansion for Hyperfine.
9 Apr
Hyperfine, Inc. (HYPR) receives CE Mark and UKCA Mark for next-generation Swoop® portable MRI system and latest Optive AI™ software advancement, enabling market access in Europe and UK. CE and UKCA approvals for next-gen Swoop system and Optive AI enable European and UK market entry, driving significant international revenue growth and competitive positioning.
24 Mar
Hyperfine, Inc. (HYPR) received $40 million from Horizon to expand its Swoop System. $40M funding from Horizon directly fuels Swoop System expansion, providing major capital for growth and strengthening market position.
23 Mar
Horizon Technology Finance has provided a $40 million loan facility to Hyperfine, Inc. (HYPR) to support its growth initiatives. $40 million loan facility delivers substantial capital infusion to fuel Hyperfine's expansion and operational stability.
19 Mar
Hyperfine (HYPR) Q4 2025 earnings call transcript covers financial results, operational updates, and forward-looking statements. Q4 earnings transcripts disclose financial metrics, guidance, and strategies that drive investor sentiment and stock trajectory.
Hyperfine, Inc. (HYPR) released Q4 2025 earnings call summary detailing financial results, operational updates, and forward guidance. Q4 earnings summary discloses key financial metrics and strategic outlook directly influencing investor sentiment and stock trajectory.
18 Mar
Hyperfine Inc. (HYPR) posted record revenue growth in Q4 2025 earnings call, driven by strategic advances including expanded market access, product enhancements, and partnerships boosting future outlook. Record revenue growth and strategic advances represent major financial and operational milestones likely to elevate investor sentiment and trajectory.